je.st
news
Tag: lexicon
How hops could become part of beer's marketing lexicon - comment
2020-11-25 11:22:00| Daily beverage news and comment - from just-drinks.com
In days gone by, the role of hops in brewing was only of interest to the true beer aficionado. Times have changed and, with the advent of the craft brewing boom, consumers know more about hops than brand owners give them credit for. Category commentator Stephen Beaumont believes this awareness offers a marketing opportunity for beer brands big and small.
Tags: part
comment
marketing
beers
Equities Analysts Issue Forecasts for Lexicon Pharmaceuticals, Inc.'s FY2020 Earnings
2016-03-04 04:50:54| Biotech - Topix.net
Lexicon Pharmaceuticals, Inc. - Stock analysts at Wedbush issued their FY2020 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, according to Zacks Investment Research . Wedbush analyst L. Moussatos forecasts that the firm will earn $2.71 per share for the year.
Tags: issue
earnings
analysts
forecasts
Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q4 2015 Results - Earnings Call Transcript
2016-03-02 00:47:31| Biotech - Topix.net
Good morning. My name is Victoria, and I will be your conference operator today.
Tags: results
call
ceo
earnings
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
2014-10-22 15:11:12| Biotech - Topix.net
Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.
Tags: enter
agreement
licensing
lexicon
Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
2014-02-05 07:12:10| drugdiscoveryonline News Articles
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization
Tags: development
focus
programs
preparation